Journal of Microbial & Biochemical Technology

Emerging Biotechnologies for Microbial Production of High-Value Bioactive Compounds

Furong Thenuwara^* Department of Biotechnology and Food Microbiology, Warsaw University of Life Sciences, Warsaw, Poland
^*Correspondence: Furong Thenuwara, Department of Biotechnology and Food Microbiology, Warsaw University of Life Sciences, Warsaw, Poland, Email:

Received: 26-Nov-2024, Manuscript No. JMBT-24-27934; Editor assigned: 28-Nov-2024, Pre QC No. JMBT-24-27934; Reviewed: 12-Dec-2024, QC No. JMBT-24-27934; Revised: 20-Dec-2024, Manuscript No. JMBT-24-27934; Published: 26-Dec-2024, DOI: 10.35248/1948-5948.24.16.633

Description

The increasing demand for high-value bioactive compounds molecules with beneficial effects on health, agriculture and industry has sparked significant interest in developing sustainable and cost-effective production methods. Traditionally, many of these bioactive compounds have been derived from natural sources such as plants, animals, or chemical synthesis. However, limitations such as low yields, the environmental impact of extraction processes and the reliance on non-renewable resources have prompted a shift towards microbial production systems. Microorganisms, such as bacteria, fungi and yeasts, have emerged as powerful platforms for producing high-value bioactive compounds due to their rapid growth, genetic manipulability and ability to produce complex molecules in large quantities. Recent advances in biotechnology, including synthetic biology, metabolic engineering and fermentation optimization, are driving the development of microbial systems that can efficiently produce a diverse array of bioactive compounds, ranging from pharmaceuticals and nutraceuticals to agricultural chemicals and industrial enzymes [1].

One of the key advantages of using microorganisms for bioactive compound production is their ability to synthesize complex natural products that are otherwise difficult or costly to obtain. For instance, antibiotics, anti-cancer agents and immunosuppressants are traditionally derived from natural sources such as soil bacteria and fungi. However, the supply of these natural resources is often limited and the extraction processes can be inefficient and environmentally damaging. Microbial production offers a more sustainable alternative, as microorganisms can be cultured in controlled environments, leading to higher yields and reduced costs. Moreover, genetic manipulation of microorganisms allows for the optimization of production pathways and the introduction of novel biosynthetic routes, enabling the production of compounds that may not be naturally synthesized by the organism [2].

One of the most exciting areas in microbial production of bioactive compounds is the use of synthetic biology to redesign microbial metabolism. Synthetic biology involves the construction and modification of biological parts, devices and systems to create new or improved functions within microorganisms. By introducing synthetic gene pathways, researchers can enable microorganisms to produce bioactive compounds that are not native to them. This is particularly important for the production of high-value compounds that may not be easily extracted from natural sources or require extensive chemical synthesis. For example, engineered Escherichia coli strains have been developed to produce the anti-cancer drug, paclitaxel, by incorporating biosynthetic pathways from the Taxus plant, which is the natural source of paclitaxel. Similarly, other compounds, such as cannabinoids, flavonoids and terpenes, have been successfully synthesized in microbes using synthetic biology techniques. This approach not only makes the production of these compounds more sustainable but also allows for the fine-tuning of their chemical structures to improve their efficacy and bioactivity [3].

In addition to synthetic biology, metabolic engineering plays a major role in optimizing microbial production of bioactive compounds. Metabolic engineering involves the modification of microbial pathways to increase the flux of precursor molecules into the biosynthesis of the desired bioactive compound. This is achieved by overexpressing genes involved in key metabolic steps, knocking down competing pathways, or introducing heterologous enzymes to enhance product formation. For example, the production of biofuels, such as ethanol or butanol, has been significantly improved through the application of metabolic engineering strategies in Saccharomyces cerevisiae and Clostridium species. Similarly, the production of secondary metabolites such as antibiotics (e.g., penicillin) and anti-cancer compounds (e.g., doxorubicin) has been enhanced by optimizing the microbial host’s metabolism. One notable example is the engineering of Streptomyces strains to improve the yield of natural antibiotics. By optimizing precursor availability and modifying regulatory networks, these engineered strains can produce larger quantities of bioactive compounds, making microbial production more economically viable [4].

Fermentation optimization is another important biotechnology that supports the microbial production of high-value bioactive compounds. Fermentation, which involves growing microorganisms in bioreactors under controlled conditions, is a critical step in the production of bioactive compounds. By optimizing factors such as temperature, pH, nutrient supply, oxygen levels and agitation, researchers can significantly increase the yield and productivity of microbial fermentation processes. Advanced bioreactor designs, such as fed-batch and continuous fermentation systems, allow for better control over the growth environment and more efficient use of nutrients, leading to improved productivity and reduced production costs. Moreover, advances in real-time monitoring and control technologies have enabled the optimization of fermentation processes through feedback loops, allowing for dynamic adjustments to maximize the production of desired compounds [5].

In addition to traditional fermentation methods, the use of alternative substrates for microbial cultivation is gaining attention in the production of bioactive compounds. One of the challenges of microbial production is the cost of raw materials, particularly carbon sources such as glucose. To reduce costs and improve sustainability, researchers are exploring the use of alternative feedstocks, such as agricultural waste, lignocellulosic biomass, or even CO₂, as carbon sources for fermentation. This not only helps reduce the environmental impact of the production process but also contributes to the circular economy by converting waste materials into valuable bioactive compounds. For example, Saccharomyces cerevisiae and Aspergillus species have been engineered to utilize non-traditional carbon sources, enabling the production of bioactive compounds from renewable and waste materials [6].

Another emerging biotechnology for improving microbial production of bioactive compounds is the use of co-culture systems. For example, co-cultures of Escherichia coli and Saccharomyces cerevisiae have been used to produce high-value bioactive compounds such as flavonoids and terpenes, with each microorganism contributing specific enzymes or metabolites to the biosynthesis process. Co-culture systems also offer the potential for enhancing product diversity by combining different microbial species with complementary biosynthetic capabilities [7].

Finally, advancements in analytical techniques, such as highthroughput screening, metabolomics and genomics, are enabling the identification and optimization of microbial strains that can efficiently produce high-value bioactive compounds. Through these methods, researchers can rapidly assess the metabolic profiles of microbial strains, identify potential bottlenecks in biosynthesis and screen for strains with enhanced production capabilities. The integration of these tools with computational modeling and systems biology approaches allows for the rational design of microbial strains and fermentation processes, accelerating the development of efficient production platforms [8-10].

References

1. Nourbakhsh F, Lotfalizadeh M, Badpeyma M, Shakeri A, Soheili V. From plants to antimicrobials: Natural products against bacterial membranes. Phytother Res 2022;36(1):33-52.

   [Crossref] [Google Scholar]

2. Sun J, Rutherford ST, Silhavy TJ, Huang KC. Physical properties of the bacterial outer membrane. Nat Rev Microbiol 2022;20(4):236-248.

   [Crossref] [Google Scholar]

3. Enriquez FA, Ahring BK. Strategies to overcome mass transfer limitations of hydrogen during anaerobic gaseous fermentations: A comprehensive review. Bioresour Technol 2023;377:128948.

   [Google Scholar]

4. Behin J, Amiri P. A review of recent advances in airlift reactors technology with emphasis on environmental remediation. J Environ Manage 2023;335:117560.

   [Google Scholar]

5. Ayodele T, Alarape K, Bello IA, Tijani A, Musiliu L, Hammed A. Microbial protein production using lignocellulosic biomass (switchgrass) and klebsiella oxytoca M5A1—A nitrogen fixer. Sustain. 2024;16(13):5486.

   [Crossref] [Google Scholar]

6. Yen HW, Chang JT. Growth of oleaginous Rhodotorula glutinis in an internal-loop airlift bioreactor by using lignocellulosic biomass hydrolysate as the carbon source. J Biosci Bioeng 2015;119(5):580-584.

   [Crossref] [Google Scholar] [PubMed]

7. Melkonian EA, Schury MP. Biochemistry, anaerobic glycolysis.

   [Google Scholar]

8. Abdel-Rahman MA, Tashiro Y, Sonomoto K. Recent advances in lactic acid production by microbial fermentation processes. Biotechnol Adv 2013;31(6):877-902.

   [Crossref] [Google Scholar]

9. Huo G, Foulquie-Moreno MR, Thevelein JM. Development of an industrial yeast strain for efficient production of 2, 3-butanediol. Microb Cell Fact 2022 ;21(1):199.

   [Crossref] [Google Scholar]

10. Gonzalez-Garcia RA, McCubbin T, Navone L, Stowers C, Nielsen LK, Marcellin E. Microbial propionic acid production. Ferment. 2017;3(2):21.

    [Crossref] [Google Scholar]